Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
about
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsClinical Pharmacology and Cardiovascular Safety of NaproxenUse of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran communityPharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.The electroacupuncture-induced analgesic effect mediated by 5-HT1, 5-HT3 receptor and muscarinic cholinergic receptors in rat model of collagenase-induced osteoarthritis.Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies.Polygoni Rhizoma inhibits inflammatory response through inactivation of nuclear factor-kappaB and mitogen activated protein kinase signaling pathways in RAW264.7 mouse macrophage cells.Inhibition of cyclooxygenases by dipyrone.
P2860
Q28305100-33AD9D99-B068-450D-A331-D620D2748B77Q30360728-A6F43387-26B1-43A7-85E9-8E72DCD1AC6EQ33906348-7B75AA72-2618-44AB-8F6A-EE000EC91852Q34389006-F0F64DD0-1450-4302-BD42-934703EAE30DQ36076445-74117A37-69FF-43C0-A3EA-E19C148155E8Q36498885-F499C748-8F71-4EBB-A292-308B06E27E92Q36904910-171F27E0-A905-49B0-AD03-EA3E02C290C4Q38201752-E5AF06D0-F616-469F-88A4-A9F9BDD939C4Q39529313-A0716205-9DD2-4F99-B0C5-49E135AE4021Q41587028-F9823BDE-3C0F-484A-BF04-6914E3EE3FF8
P2860
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Cardiovascular risk with cyclo ...... ubstance specific differences?
@ast
Cardiovascular risk with cyclo ...... ubstance specific differences?
@en
type
label
Cardiovascular risk with cyclo ...... ubstance specific differences?
@ast
Cardiovascular risk with cyclo ...... ubstance specific differences?
@en
prefLabel
Cardiovascular risk with cyclo ...... ubstance specific differences?
@ast
Cardiovascular risk with cyclo ...... ubstance specific differences?
@en
P2860
P1476
Cardiovascular risk with cyclo ...... ubstance specific differences?
@en
P2093
Gerd Geisslinger
P2860
P2888
P356
10.1007/S00210-006-0044-7
P577
2006-04-04T00:00:00Z